<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972025000101306</article-id>
<article-id pub-id-type="doi">10.26445/10.01.12</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Resistencia a la insulina en una población con diabetes mellitus tipo 1 como marcador de diabetes doble.]]></article-title>
<article-title xml:lang="en"><![CDATA[Insulin resistance in a population with type 1 diabetes mellitus as a marker of double diabetes.]]></article-title>
<article-title xml:lang="pt"><![CDATA[Resistência à insulina em uma população com diabetes mellitus tipo 1 como marcador de diabetes duplo.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garau]]></surname>
<given-names><![CDATA[Mariela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Di Lorenzi]]></surname>
<given-names><![CDATA[Roberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aída]]></surname>
<given-names><![CDATA[Erika]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barreneche]]></surname>
<given-names><![CDATA[Lorena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bruno]]></surname>
<given-names><![CDATA[Lorena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Marta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Airaudo]]></surname>
<given-names><![CDATA[Cecilia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Tania]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[Elena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Melone]]></surname>
<given-names><![CDATA[Iris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Noemí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[María Rosa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[Sebastián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Curbelo]]></surname>
<given-names><![CDATA[Milena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,aff1  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Montevideo  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>10</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972025000101306&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972025000101306&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972025000101306&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La Diabetes Mellitus (DM) es una patología de alta prevalencia a nivel mundial y en nuestro país. La Diabetes Doble (DD) define un grupo de pacientes con características de DM tipo 1 (DM1) y predisposición genética y fenotípica para DM2 (DM2) e insulino resistencia (IR) y se asocia a mayor prevalencia de complicaciones microangiopáticas de la DM, enfermedad cardiovascular y mayor mortalidad. La IR puede estimarse en la práctica clínica a través de la tasa estimada de captación de glucosa (estimated Glucose Disposal Rate - eGDR).  Metodología:  estudio descriptivo, observacional, transversal con el objetivo de conocer la prevalencia de DD en una población con DM1 y su relación con variables clínicas -paraclínicas.  Resultados:  De los 76 pacientes captados, 45 (59.2%) eran hombres, con una mediana de edad de 25 (19 - 40) años, con un tiempo de evolución de la DM promedio de 10 años (7 - 15). 32.9% tenía obesidad y 11.8% sobrepeso. El promedio de hemoglobina glicosilada (HbA1c) fue de 9.2 ± 1.8. Tenía retinopatía el 19.1% y el índice albuminuria/creatinuria fue patológico en 25%. Se encontró DD en el 58.7%; que se asoció en forma significativa con la edad, así como con la presencia de hipertensión arterial, HbA1c e índice de masa corporal.  Discusión:  La prevalencia de DD es similar a otros estudios internacionales, se trata de pacientes añosos, con mayor número de repercusiones microangiopáticas.  Conclusiones:  Identificar a esta población es fundamental para tomar conductas agresivas en el control de los factores de riesgo cardiovasculares, así como intervenciones para mejorar el control glucémico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Diabetes Mellitus (DM) is a highly prevalent disease worldwide and in Spain. Double Diabetes (DD) defines a group of patients with characteristics of type 1 DM (T1DM) and a genetic and phenotypic predisposition for type 2 DM (T2DM) and insulin resistance (IR). It is associated with a higher prevalence of microangiopathic complications of DM, cardiovascular disease, and higher mortality. IR can be estimated in clinical practice using the estimated glucose disposal rate (eGDR).  Methodology:  This was a descriptive, observational, cross-sectional study aimed at determining the prevalence of DD in a population with T1DM and its relationship with clinical and paraclinical variables.  Results:  Of the 76 patients enrolled, 45 (59.2%) were men, with a median age of 25 (19-40) years, and an average DM onset of 10 years (7-15). 32.9% were obese, and 11.8% were overweight. The mean glycated hemoglobin (HbA1c) was 9.2 ± 1.8. Retinopathy was present in 19.1% of patients, and the albuminuria/creatinuria ratio was abnormal in 25%. DD was found in 58.7% of patients; this was significantly associated with age, as well as with the presence of hypertension, HbA1c, and body mass index.  Discussion:  The prevalence of DD is similar to other international studies; these are older patients with a greater number of microangiopathic repercussions.  Conclusions:  Identifying this population is essential for aggressive interventions to control cardiovascular risk factors and for interventions to improve glycemic control.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  O Diabetes Mellitus (DM) é uma doença altamente prevalente em todo o mundo e na Espanha. O Diabetes Duplo (DD) define um grupo de pacientes com características de DM tipo 1 (DM1) e predisposição genética e fenotípica para DM tipo 2 (DM2) e resistência à insulina (RI). Está associado a uma maior prevalência de complicações microangiopáticas do DM, doenças cardiovasculares e maior mortalidade. A RI pode ser estimada na prática clínica por meio da taxa estimada de descarte de glicose (eGDR).  Metodologia:  Este foi um estudo descritivo, observacional e transversal com o objetivo de determinar a prevalência de DD em uma população com DM1 e sua relação com variáveis &#8203;&#8203;clínicas e paraclínicas.  Resultados:  Dos 76 pacientes incluídos, 45 (59,2%) eram homens, com mediana de idade de 25 (19-40) anos e tempo médio de início do DM de 10 anos (7-15). 32,9% eram obesos e 11,8% apresentavam sobrepeso. A hemoglobina glicada média (HbA1c) foi de 9,2 ± 1,8. Retinopatia esteve presente em 19,1% dos pacientes, e a relação albuminúria/creatinúria foi anormal em 25%. DD foi encontrada em 58,7% dos pacientes; isso foi significativamente associado à idade, bem como à presença de hipertensão, HbA1c e índice de massa corporal.  Discussão: A prevalência de DD é semelhante à de outros estudos internacionais; trata-se de pacientes mais velhos com maior número de repercussões microangiopáticas.  Conclusões:  A identificação dessa população é essencial para intervenções agressivas no controle dos fatores de risco cardiovascular e para intervenções que melhorem o controle glicêmico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[diabetes mellitus]]></kwd>
<kwd lng="es"><![CDATA[diabetes doble]]></kwd>
<kwd lng="es"><![CDATA[insulino resistencia]]></kwd>
<kwd lng="es"><![CDATA[tasa estimada captación de glucosa]]></kwd>
<kwd lng="en"><![CDATA[diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[double diabetes]]></kwd>
<kwd lng="en"><![CDATA[insulin resistance]]></kwd>
<kwd lng="en"><![CDATA[estimated glucose uptake rate]]></kwd>
<kwd lng="pt"><![CDATA[diabetes mellitus]]></kwd>
<kwd lng="pt"><![CDATA[diabetes duplo]]></kwd>
<kwd lng="pt"><![CDATA[resistência à insulina]]></kwd>
<kwd lng="pt"><![CDATA[taxa estimada de captação de glicose]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magliano]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Boyko]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<collab>IDF Diabetes Atlas 10th edition scientific committee</collab>
<source><![CDATA[IDF DIABETES ATLAS]]></source>
<year>2021</year>
<edition>10th edition</edition>
<publisher-loc><![CDATA[Brussels ]]></publisher-loc>
<publisher-name><![CDATA[International Diabetes Federation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Encuesta de prevalencia de la diabetes en Uruguay Primera fase: Montevideo. Año 2004]]></article-title>
<source><![CDATA[Arch Med Int]]></source>
<year>2005</year>
<volume>27</volume>
<page-range>7-12</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uruguay Ministerio de Salud Pública]]></surname>
</name>
</person-group>
<source><![CDATA[PPENT P de prevención de las enfermedades no transmisibles. Primera encuesta nacional de factores de riesgo de enfermedades no transmisibles]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[MSP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uruguay Ministerio de Salud Pública]]></surname>
</name>
</person-group>
<source><![CDATA[PPENT P de prevención de las enfermedades no transmisibles. Segunda encuestra nacional de factores de riesgo de enfermedades no transmisibles]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[MSP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association Professional Practice Committee</collab>
<article-title xml:lang=""><![CDATA[2 Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2024</year>
<volume>47</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S20-42</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teupe]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bergis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiological evidence for &amp;raquo;,» &amp;reg;,® &amp;sect;,§ &amp;shy;,­ &amp;sup1;,¹ &amp;sup2;,² &amp;sup3;,³ &amp;szlig;,ß &amp;THORN;,Þ &amp;thorn;,þ &amp;times;,× &amp;Uacute;,Ú &amp;uacute;,ú &amp;Ucirc;,Û &amp;ucirc;,û &amp;Ugrave;,Ù &amp;ugrave;,ù &amp;uml;,¨ &amp;Uuml;,Ü &amp;uuml;,ü &amp;Yacute;,Ý &amp;yacute;,ý &amp;yen;,¥ &amp;yuml;,ÿ &amp;para;,¶ double diabetes &amp;raquo;,» &amp;reg;,® &amp;sect;,§ &amp;shy;,­ &amp;sup1;,¹ &amp;sup2;,² &amp;sup3;,³ &amp;szlig;,ß &amp;THORN;,Þ &amp;thorn;,þ &amp;times;,× &amp;Uacute;,Ú &amp;uacute;,ú &amp;Ucirc;,Û &amp;ucirc;,û &amp;Ugrave;,Ù &amp;ugrave;,ù &amp;uml;,¨ &amp;Uuml;,Ü &amp;uuml;,ü &amp;Yacute;,Ý &amp;yacute;,ý &amp;yen;,¥ &amp;yuml;,ÿ &amp;para;,¶]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1991</year>
<volume>337</volume>
<numero>8737</numero>
<issue>8737</issue>
<page-range>361-2</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chillarón]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Goday]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pedro-Botet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome metabólico, diabetes mellitus tipo 1 y resistencia a la insulina]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2008</year>
<volume>130</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>466-70</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk in double diabetes mellitus--when two worlds collide]]></article-title>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2012</year>
<volume>8</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>476-85</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kilpatrick]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Rigby]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Atkin]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes &amp;raquo;,» &amp;reg;,® &amp;sect;,§ &amp;shy;,­ &amp;sup1;,¹ &amp;sup2;,² &amp;sup3;,³ &amp;szlig;,ß &amp;THORN;,Þ &amp;thorn;,þ &amp;times;,× &amp;Uacute;,Ú &amp;uacute;,ú &amp;Ucirc;,Û &amp;ucirc;,û &amp;Ugrave;,Ù &amp;ugrave;,ù &amp;uml;,¨ &amp;Uuml;,Ü &amp;uuml;,ü &amp;Yacute;,Ý &amp;yacute;,ý &amp;yen;,¥ &amp;yuml;,ÿ &amp;para;,¶ double diabetes &amp;raquo;,» &amp;reg;,® &amp;sect;,§ &amp;shy;,­ &amp;sup1;,¹ &amp;sup2;,² &amp;sup3;,³ &amp;szlig;,ß &amp;THORN;,Þ &amp;thorn;,þ &amp;times;,× &amp;Uacute;,Ú &amp;uacute;,ú &amp;Ucirc;,Û &amp;ucirc;,û &amp;Ugrave;,Ù &amp;ugrave;,ù &amp;uml;,¨ &amp;Uuml;,Ü &amp;uuml;,ü &amp;Yacute;,Ý &amp;yacute;,ý &amp;yen;,¥ &amp;yuml;,ÿ &amp;para;,¶ in the Diabetes Control and Complications Trial]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2007</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>707-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pop]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Clenciu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Anghel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Radu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Socea]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mota]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin resistance is associated with all chronic complications in type 1 diabetes]]></article-title>
<source><![CDATA[J Diabetes]]></source>
<year>2016</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>220-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes of insulin resistance status and development of complications in type 1 diabetes mellitus Analysis of DCCT/EDIC study]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2022</year>
<volume>184</volume>
<page-range>109211</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orchard]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Erbey]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Forrest]]></surname>
<given-names><![CDATA[KYZ]]></given-names>
</name>
<name>
<surname><![CDATA[Smithline Kinder]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2003</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1374-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schauer]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Snell-Bergeon]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Maahs]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Kretowski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eckel]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes The CACTI study]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2011</year>
<volume>60</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>306-14</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nyström]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Holzmann]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Eliasson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Svensson]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Kuhl]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sartipy]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimated glucose disposal rate and long-term survival in type 2 diabetes after coronary artery bypass grafting]]></article-title>
<source><![CDATA[Heart Vessels]]></source>
<year>2017</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>269-78</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garofolo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gualdani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Scarale]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Bianchi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aragona]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Campi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lucchesi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Daniele]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Miccoli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Francesconi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Del Prato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Penno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes A 10-Year Follow-up Study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2020</year>
<volume>43</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>e139-41</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Tobin]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Andres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucose clamp technique a method for quantifying insulin secretion and resistance]]></article-title>
<source><![CDATA[Am J Physiol]]></source>
<year>1979</year>
<volume>237</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>E214-23</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishtala]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kietsiriroje]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Karam]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ajjan]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimated glucose disposal rate demographics and clinical characteristics of young adults with type 1 diabetes mellitus: A cross-sectional pilot study]]></article-title>
<source><![CDATA[Diab Vasc Dis Res]]></source>
<year>2020</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cantley]]></surname>
<given-names><![CDATA[NW]]></given-names>
</name>
<name>
<surname><![CDATA[Lonnen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kyrou]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tahrani]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Kahal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between overweight/obesity and double diabetes in adults with type 1 diabetes; a cross-sectional study]]></article-title>
<source><![CDATA[BMC Endocr Disord]]></source>
<year>2021</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>187</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Buenahora]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome metabólico y resistencia insulínica en pacientes con Diabetes Mellitus tipo 1 prevalencia]]></article-title>
<source><![CDATA[Salud Mil]]></source>
<year>2019</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-32</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrerizo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guías para el tratamiento de las dislipemias en el adulto Adult Treatment Panel III (ATP-III)]]></article-title>
<source><![CDATA[Endocrinol Nutr]]></source>
<year>2004</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>254-65</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Le]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammadi-Shemirani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Morton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brinza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surrogate Adiposity Markers and Mortality]]></article-title>
<source><![CDATA[JAMA Netw Open]]></source>
<year>2023</year>
<volume>6</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
